Celgene Corp. buy tamam
Start price
19.03.17
/
50%
€113.26
Target price
12.11.18
€127.22
Performance (%)
-41.19%
End price
12.11.18
€66.61
Summary
This prediction ended on 12.11.18 with a price of €66.61. Massive losses of -41.19% were the result for the BUY prediction by tamam. tamam has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Celgene Corp. | - | - | - | - |
iShares Core DAX® | -0.922% | -1.993% | 13.399% | 16.075% |
iShares Nasdaq 100 | 0.371% | -0.868% | 41.541% | 46.938% |
iShares Nikkei 225® | 2.224% | -5.187% | 20.497% | 4.643% |
iShares S&P 500 | -0.026% | -0.918% | 30.410% | 42.418% |
Comments by tamam for this prediction
In the thread Celgene Corp. diskutieren
Celgene is a true "buy & hold" name in the biotech sector
tamam stimmt am 19.03.2017 der Outperform-Einschätzung der institutionellen Analysten mit dem Kursziel 141.04$ zu.
(Vom Mitglied beendet)